PharVision Advisers’s Colgate-Palmolive CL Stock Holding History

PharVision Advisers’s Portfolio CL Stock Details CL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,205	Closed	-$336K	–	729
2025 Q3	$336K	Buy	+4,205	New	+$359K	0.19%	162

Other funds holding CL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PharVision Advisers's CL Position: Q4 2025 in Review

PharVision Advisers sold out of Colgate-Palmolive (CL) in Q4 2025, closing a stake of 4,205 shares — an estimated $336K sold.

PharVision Advisers first reported a position in CL in Q3 2025 and held it in 1 quarter. The position peaked at $336K in Q3 2025. 1,888 funds tracked by Wall St. Rank hold CL as of Q4 2025.

PharVision Advisers reported no remaining Colgate-Palmolive position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 4,205 Colgate-Palmolive shares in Q4 2025, an estimated $336K.
PharVision Advisers first reported a position in Colgate-Palmolive in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Colgate-Palmolive position peaked at $336K in Q3 2025.
1,888 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.